Astonea Labs Ltd

Astonea Labs Ltd

Astonea Labs Ltd has informed the BSE about a change in its Corporate Identification Number (CIN) due to an alteration of the Object Clause of its Memorandum of Association. The alteration was approved by the company's members at the Annual General Meeting on August 21, 2026. The revised CIN is L21001CH2017PLC041482, and the date of registration of the alteration is October 9, 2026.

Astonea Labs Ltd

Astonea Labs Ltd has incorporated a new subsidiary, Longevity Science Private Limited, with the company proposing to subscribe to 51% of its initial paid-up equity share capital. The subsidiary will operate in the pharmaceuticals, healthcare, nutraceuticals, and allied products industry.

Astonea Labs Ltd

Astonea Labs Ltd submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September 2026, confirming adherence to the provisions of the regulation.

Astonea Labs Ltd

Astonea Labs Ltd has announced the closure of its trading window for all Designated Persons, including directors, officers, and their immediate relatives, due to the upcoming declaration of unaudited financial results. The trading window will remain closed from October 1, 2026, until 48 hours after the results are declared. The company has also frozen the Permanent Account Numbers (PANs) of these individuals at the security level.

Astonea Labs Ltd

Astonea Labs Ltd has resubmitted its financial results for the half year ended 31.03.2025 due to discrepancies observed by BSE Limited.

Astonea Labs Ltd

Astonea Labs Ltd has approved an alteration in its Memorandum of Association to expand and align its objects with its existing and proposed business activities in the pharmaceutical, nutraceutical, healthcare, ayurvedic, and allied sectors.

Astonea Labs Ltd

Astonea Labs Ltd re-appoints Ms. Pooja Singh as Director, effective August 21, 2026, following her retirement by rotation. Ms. Singh has over eight years of experience in the pharmaceutical industry, with expertise in Quality Assurance and Drug Regulatory Affairs.

Astonea Labs Ltd

Astonea Labs Ltd has submitted the voting results and scrutinizer's report for its 9th Annual General Meeting (AGM) held on August 21, 2026, where all resolutions were approved by the members with the requisite majority.

Astonea Labs Ltd

Astonea Labs Ltd held its 9th Annual General Meeting (AGM) on August 21, 2026, where six members were present. The meeting was convened to discuss the company's financial performance for FY 2025-26, which showed revenue of approximately Rs. 148 Crore and Profit After Tax (PAT) of approximately Rs. 4.51 Crore. The meeting also discussed the adoption of the Audited Standalone and Consolidated Financial Statements, the re-appointment of Ms. Pooja Singh as a director, and the ratification of the remuneration of the Cost Auditor.

Astonea Labs Ltd

Astonea Labs Ltd has published a notice of its 9th Annual General Meeting (AGM) in newspapers and on its website, as required by SEBI regulations.

Astonea Labs Ltd

Astonea Labs Ltd has submitted its Annual Report for the Financial Year 2025-26, as per Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report includes the Notice convening the 9th Annual General Meeting, Board's Report, Audited Financial Statements, and Statutory Auditors' Report.

Astonea Labs Ltd

Astonea Labs Ltd has announced the notice of its 9th Annual General Meeting (AGM) scheduled to be held on August 21, 2026, at Mercure Hotel, Chandigarh. The meeting will consider and transact various businesses, including the adoption of audited standalone financial statements for the financial year ended March 31, 2026.

Astonea Labs Ltd

Astonea Labs Ltd has revised its tax auditor appointment under the Income-tax Act, 2025, with M/s. Avnish Sharma & Associates continuing as the tax auditor for the tax year 2026-27.

Astonea Labs Ltd

Astonea Labs Ltd has announced its audited consolidated financial results for the half year and year ended 31.03.2026, with the board of directors approving the results and authorizing the submission to the stock exchange. The results include an unmodified opinion from the statutory auditors.

Astonea Labs Ltd

Astonea Labs Ltd has announced the outcome of its Board Meeting held on 24th July, 2026, where it approved the audited consolidated financial results for the half year and financial year ended 31st March, 2026, along with the audited standalone financial results for the financial year ended 31st March, 2026. The Board also approved the declaration of the audited consolidated financial results, and the trading window for dealing in the securities of the Company has been reopened. Additionally, the Board approved the draft Board's Report for the financial year 2025-26 and the Annual Report for the financial year ended 31st March, 2026.